New Factor XIa Inhibitor Cuts Stroke Risk With Lower Bleeding: Phase III Win
Alex So, Associate Director Strategy and Digitalisation China at Merck Group, posted on LinkedIn:
”Rather than a discouraging attempt that the quoted video may suggest, it is delightful to know the factor XIa inhibitor’s potential to reduce stroke risk in patients who have had a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, as reported by its latest phase III trial for secondary stroke prevention.
Factor XIa can activate Factor IX, amplifying thrombin generation of the clotting process. As an anticoagulation strategy, the inhibition has less impact on clot stabilisation in response to injury, i.e., a lower risk of bleeding. It might be worth rementioning the siRNA drug that silences the gene producing antithrombin, a mechanism in this field applicable to haemophilia as discussed in a prior post.
The milestone success, which enables continued efforts to develop a better blood thinner despite a somewhat reduced scope and to investigate Factor XIa as a target, is encouraging.
Non-business-related therapeutics posting. Consult practitioners for medication needs.”
Stay updated with Hemostasis Today.
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026